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a b s t r a c t
We report the sensitive detection of C-reactive protein (CRP), a biomarker for cardiac disease, using a
carbon nanofiber based biosensor platform. Vertically aligned carbon nanofibers were grown using
plasma enhanced chemical vapor deposition to fabricate nanoelectrode arrays in a 33 configuration.
Cyclic voltammetry (CV) and electrochemical impedance spectroscopy (EIS) were used for the CRP
detection. The CV responses show a 25% reduction in redox current upon the immobilization of anti-CRP
on the electrode where as a 30% increase in charge transfer resistance is seen from EIS. Further reduction
in redox current and increase in charge transfer resistance result from binding of CRP on anti-CRP
immobilized surface, proportional to the concentration of the CRP target. The detection limit of the
sensor is found to be 90 pM or 11 ng/ml, which is in the clinically relevant range. Control tests using
non-specific myoglobin antigen confirmed the specificity of the present approach.
Published by Elsevier B.V.
1. Introduction
Detection and quantification of biomarkers for acute myocar-
dial infraction (AMI) is critical in the diagnosis of cardiovascular
diseases. Traditional diagnosis methods for cardiovascular diseases
are time consuming and expensive since they are primarily
conducted at central clinical laboratories. Faster and inexpensive
diagnosis through point-of-care, lab-on-a chip type systems is
highly desirable (Mohammed and Desmulliez, 2011). Cardiac
troponin (cardiac troponin T (cTnT) and cardiac troponin I (cTnI)),
CK-MB (one of the three isoenzyme forms of creatine kinase (CK))
and myoglobin are known as the definitive biomarkers and their
elevated concentration in blood remains maintained from few
hours to several days upon the occurrence of AMI (Yang and Zhou,
2006). Biomarkers specific to systemic inflammation (SI), a state
that occurs much earlier to myocardial necrosis, include C-reactive
protein (CRP), myeloperoxidase (MPO), P-selectine etc. and these
are known as the biomarkers for earlier detection of acute
coronary syndrome (Yang and Zhou, 2006). Among these, CRP,
an acute phase protein, is very sensitive and specific to SI, which is
synthesized in liver and secreted into blood stream causing
infection or inflammation (Du Clos, 2000). The blood plasma
concentration of CRP, which increases rapidly several orders
during the SI state, can therefore predict future chances of AMI
and hence, can help in risk stratification and implementing
appropriate and timely therapeutic procedures (Tsai et al., 2007).
A rapid and early diagnosis of cardiovascular disease should
therefore involve the testing for a definite biomarker (cardiac
Troponin, CK-MB or myoglobin) in combination with an early
biomarker (C-reactive protein) (Apple et al., 2005).
C-reactive protein has thus become an important candidate for
the early detection of cardiovascular events and for setting up
preventive measures to reduce the number of deaths due to AMI.
There are three different levels of CRP concentrations, suggested
by the American Heart Association and the United States Center
for Disease control, in human blood serum that evaluates the
cardiovascular disease risk: CRP concentration less than 1 μg/ml
represents a low risk state, concentration between 1 and 3 μg/ml
is considered as average risk and any concentration above 3 μg/ml
represents high risk (Bryan et al., 2013; Kushner and Sehgal, 2002).
Various studies have proved CRP as a strong predictor of life
threatening events such as AMI, giant cell arteritis, arterial disease,
stroke and cardiac arrest causing sudden death (Kervinen et al.,
2001). Its concentration level in blood rises from a normal level of
r5 μg/ml to 4100 μg/ml in case of systemic infections (Tsai et al.,
2007). The reliable means of detection and quantification of CRP
concentration thus becomes important for accurate implementa-
tion of therapeutic interventions before and after AMI occurrence
for monitoring the status of AMI patients. Besides the traditional
expensive and time-consuming methods of CRP testing (Roberts et
Contents lists available at ScienceDirect
journal homepage: www.elsevier.com/locate/bios
Biosensors and Bioelectronics
http://dx.doi.org/10.1016/j.bios.2014.03.027
0956-5663/Published by Elsevier B.V.
n Corresponding author.
E-mail address: Jessica.E.Koehne@nasa.gov (J.E. Koehne).
Biosensors and Bioelectronics 59 (2014) 112–119
al., 2000), quantification of CRP using surface plasmon resonance
based biosensors (Hu et al., 2006), optical and acoustic biosensors
(Luchansky et al., 2011; McBride and Cooper., 2008), enzyme-
linked immunosorbent assay (ELISA) (Leung et al., 2005), fluores-
cence based biosensors (Wolf et al., 2004), magnetic biosensors
(Tsai et al., 2007; Martin et al., 2007), electrochemical biosensors
based on gold electrode (Bryan et al., 2013; Hennessey et al.,
2009), magnetic nano-particles (Tsai et al., 2007) etc., has been
demonstrated with a wide range of sensitivity, specificity, cost,
turn around time (TAT), immunoassay complexity, flexibility for
multiplexing, and detection limit (Qureshi et al., 2012).
Among the available techniques, electrochemical based biosen-
sors have been one of the most successful in offering less
expensive, faster, simpler, portable, accurate, flexible for multi-
plexing and label free detection of a wide range of proteins, nucleic
acids, enzymes and other biomolecules. In addition, with the
advancements in bioelectronics and biosensors technology using
materials such as carbon nanotubes (CNTs) (single and multi-
walled) (Jacobs et al., 2010), carbon nanofibers (CNFs) (Li et al.,
2012; Vamvakaki et al., 2006) graphene (Kuila et al., 2011), gold
nano-wires, nano-structures (Das and Kelley, 2011) and other
inorganic wires (Meyyappan and Sunkara, 2010), the sensitivity
and detection limits for proteins, nucleic acids etc. have improved
tremendously in recent years. Among carbon nanostructures,
vertically aligned carbon nanofibers (VACNFs), where each fiber
is an individual freestanding nanostructure and acts as a nanoe-
lectrode, have been used successfully to construct biosensors (Li et
al., 2005; Cassell et al., 2009; Koehne et al., 2009; Arumugam et al.,
2009, 2010; Siddiqui et al., 2010; Periyakaruppan et al., 2011)
including detection of cardiac troponin (Periyakaruppan et al.,
2013). Due to their small diameter, robustness, high conductivity,
biocompatibility and ease of surface modification, VACNF based
nanoelectrode arrays (NEAs) serve as a biosensor platform. These
VACNFs are typically grown by plasma enhanced chemical vapor
deposition (PECVD) wherein the inherent vertical electric field on
the substrate platform helps to orient the carbon nanofibers
vertically. The VACNFs can be randomly placed on the wafer like
a forest or can be precisely positioned at predetermined spots by
patterning the growth catalyst on the wafer (Arumugam et al.,
2009, 2010; Siddiqui et al., 2010). The nanoelectrode array can be
employed with conventional electrochemical techniques such as
cyclic voltammetry (CV) (Nicholson, 1965), differential pulse
voltammetry (DPV) (Brown and Anson, 1977), and electrochemical
impendence spectroscopy (EIS) (Brown and Anson, 1977). Here we
use a nanoelectrode array with patterned VACNFs for the detec-
tion and quantification of C-reactive protein using both CV and EIS
and obtain a detection limit of 90 pM.
2. Materials and methods
2.1. Chemicals and regents
C-reactive protein (2.1 mg protein per ml (lowry)) from human
plasma and anti-human C-reactive protein (anti-CRP, 54.7 mg
protein per ml (Biuret)) antibody (produced in goat), anti-
myoglobin (produced in rabbit, 1:500 protein dilution) as control
antibody, myoglobin from human heart (Z95%, SDS-PAGE, 2 mg
protein per ml (lowry)) as control antigen, 1-ethyl-3-(3-dimethyla-
minopropyl) carbodiimide (EDC, Z99%) and N-hydroxysuccinimide
sodium salt (sulfo-NHS, Z98% (HPLC)) were purchased from Sigma
Aldrich (Saint Louis MO). The stock CRP solution was stored at 4 1C
whereas the anti-CRP, anti-myoglobin and myoglobin solutions
were stored at 20 1C. Highly pure de-ionized water (18.2 MΩ cm)
from super-Q Millipore system was used throughout the study.
Phosphate buffered saline (PBS, 10 mM, pH 7.4) was prepared by
dissolving PBS sachet (from Sigma Aldrich) in de-ionized water and
was filtered using a 0.22 μm membrane filter before every use.
Sodium hydroxide (NaOH, 1 mM) solution, for electrochemical
etching, was prepared by dissolving appropriate quantity of NaOH
pellets (from Sigma Aldrich) in de-ionized water. For continuous
use, the anti-CRP solution was stored at 4 1C in working aliquots.
Potassium hexacyanoferrate (III) for probe molecule (Fe[CN6]3 /4)
and all other regents used in the study were of analytic grade.
2.2. Nanoelectrode array fabrication using e-beam patterned VACNFs
A 4-inch silicon (100) wafer with 500 nm thermal oxide layer
consists of 30 devices (or chips). Each device contains nine
identical micro pads (electrodes), each with a surface area of
40,000 μm2, arranged in 33 array format as shown in Fig. S1(a)
(Supporting Information). Each electrode is interconnected to an
individual contact pad (1 mm) for external electrical contact. A
brief account of the fabrication procedure is given here. A 200 μm
thick chromium (Cr) layer was deposited by e-beam evaporation
on optolithographically defined electrodes, contact pads and
electrical interconnects. Then the electrodes (micro pads) were
spun coated with 400 nm poly(methyl methacrylate) (PMMA) and
patterned by using e-beam current (2 nA, 1950 μC/cm2 at
100 keV). A 10 nm Cr adhesion layer followed by 30 nm nickel
catalyst layer were further deposited on these e-beam patterned
electrodes. VACNFs were grown from these patterned Ni catalyst
particles (Arumugam et al., 2009) using a DC-biased PECVD system
(Aixtron, Cambridge, UK). The growth recipe includes acetylene
(C2H2, 125 sccm) feedstock for carbon source diluted with ammo-
nia (NH3, 444 sccm) at a pressure of 6.3 mbar, 700 1C and plasma
power of 180 W. A 15 min deposition yields 39,000 free standing
VACNFs spaced 1 μm apart on each patterned electrode, where
each fiber has a tip diameter of 80 nm, base diameter of
100 nm and an average height of 1.5 μm with Ni catalyst
particle on the tip. Passivation of CNF sidewalls and the underlying
Cr layer was done by depositing a 3 μm silicon oxide (SiO2) layer
using CVD and employing tetraethylorthosilicate (TEOS) vapor
precursor from a liquid source. Planarization of the top electrode
surface and exposure of fibers tips were achieved by chemical
mechanical polishing (CMP) in two steps, using 0.5 μm alumina
(pH 4) for stock removal and 0.1 μm alumina (pH 4) for final
polish. Contact pads for electric connection were exposed by
optical lithography using a 2.5 μm thick Shipley 3012 resist. Finally
the wafer was diced into 30 equal size (14 mm squares) chips
containing nine electrically isolated electrodes (33 format,
200 μm squares) interconnected with nine contact pads (1 mm
squares) for electrical connections. Fig. S1(b) and (c) shows
magnified scanning electron microscopy (SEM) (S-4000, Hitachi,
USA) images of an individual electrode and VACNF tips embedded
in oxide layer. Fig. S1(d) shows an AFM image of the electrode's
surface topography with the line section showing the height
profile and Fig. S1(e) depicts the 3D schematic of NEA, working
electrode along with the exposed fiber tip (Fig. S1(f)).
2.3. Electrochemical characterization
All electrochemical measurements were carried out using a
standard three electrodes electrochemical cell connected to a
H-CHI660D Instrument, Electrochemical Workstation/Analyzer
(CHI Instruments, Inc., Austin, TX). The instrument was interfaced
to a personal computer and controlled by associated data proces-
sing/analyzing software, chi660d. The electrochemical cell consists
of high quality platinum (Pt) wire as counter electrode, saturated
calomel electrode (SCE, Accumet, New Hampshire, USA) as refer-
ence electrode and nine identical working electrodes of VACNF
NEAs connected in a custom designed Teflon liquid cell. The Teflon
R.K. Gupta et al. / Biosensors and Bioelectronics 59 (2014) 112–119 113
liquid cell defines an O-ring of 3 mm diameter and nine connect-
ing pins for electrical contacts to individual working electrodes
through contact pads. A 5 mM K3[Fe(CN)6] in 1 M KCl electrolyte
solution was used to evaluate the electrode characteristics using
cyclic voltammetry (CV) and electrochemical impendence spectro-
scopy (EIS) techniques, before and after modifying the electrode
surface with selective probes and target proteins.
2.4. Pre-conditioning of the nanoelectrode array
Before using the e-beam patterned VACNF NEA for bare electrode
characteristics or probe/target immobilization, a final polishing step
was carried out using non-crystallizing colloidal silica suspension
(0.02 μm, from Buehler) on polishing pad (MicroCloth, 73 mm Dia,
from Buehler) for 5–7 min, followed by rinsing with isopropyl alcohol
(IPA) and de-ionized water and sonication in de-ionized water for
15 min. This final polishing removes the residual debris off the CNF
tips, which resulted from the prior CMP procedure. Following
sonication, the devices were soaked in nitric acid (HNO3) for
30 min for two reasons: one is to further clean the CNFs surface
and the second is to generate carboxylic acid groups (–COOH)
through oxidation on the CNF tips. The devices were then rinsed
with de-ionized water and stored in petri dish before use.
2.5. Surface functionalization and probe (anti-CRP) immobilization
Fig. S2(a–c) shows the schematics of electrode surface functio-
nalization and modifications for probes and target bindings.
Freshly created carboxylic acid groups on the CNFs tips (Fig. S2
(a)) were used for probe (anti-CRP) immobilization using carbo-
diimide crosslinking. Prior to probe immobilization and in order
for stable terminal activation of carboxylic acid groups, a reaction
of coupling regents (linker) solution containing 0.4 M EDC and
0.1 M sulfo-NHS in PBS (10 mM, pH 7.4 and 1:1 volume) was
carried out with VACNFs for 30 min. The functionalized devices
(with linker molecules) were then rinsed gently with PBS twice for
10 min to remove unstable (loosely attached) linker molecules off
the electrodes surface and the devices were later allowed to dry at
room temperature. Following the linker functionalization, 50 μL of
anti-CRP (20 μM) solution in PBS (10 mM, ph 7.4) was spotted to
the VACNFs in the electrode and incubated at room temperature
for one hour. The reaction between the primary amine groups in
anti-CRP and –COOH groups at the VACNF tips resulted in the
formation of stable amide bonds between anti-CRP and VACNFs as
shown in Fig. S2(b). Loosely-bonded anti-CRP and other non-
specific bindings were eliminated from the electrode surface by
stringent rinsing for 15 min in three steps; twice with PBS
(25 min) and once with de-ionized water (5 min) while shaking
the device at room temperature. Prior to electrochemistry readout,
rinsing with de-ionized water was necessary to remove PBS from
the electrode surface with anti-CRP immobilized on VACNF tips.
After the electrochemical readout, the devices were rinsed gently
with de-ionized water and allowed to dry before incubating
specific concentration of CRP on anti-CRP immobilized electrode
surface.
2.6. CRP binding to immobilized anti-CRP probes
For evaluating the limit of detection (LOD) of the sensors,
different concentrations (from 50 ng/ml to 5 μg/ml) of CRP were
prepared by adding specific quantity of CRP from the stock
concentration (2.1 mg/ml) in different amounts of PBS (10 mM,
pH 7.4). A known concentration of CRP was allowed to react and
covalently bind with anti-CRP probes for 1 h by dropping the CRP
solution on the device. The schematic shown in Fig. S2
(c) represents the specific CRP binding with anti-CRP. Non-
specifically attached molecules (by-products) were removed by
stringent rinsing of the device for 15 min in three steps: twice
with PBS (25 min) and once with de-ionized water (5 min)
whilst shaking the device at room temperature. The devices were
allowed to dry before taking the electrochemical readout.
2.7. Detection and quantification of target CRP
Electrochemical techniques (CV and EIS) were employed for
qualitative as well as quantitative detection of CRP. CV and EIS data
characterizing bare working electrodes and subsequent VACNF
surface modifications (Linker\anti-CRP\CRP) were acquired using
the addition of ([Fe(CN)6]3/4) in the potential region of its
reduction and oxidation. CV data sets were recorded in the
potential window from 400 mV to 800 mV vs. SCE at 20 mV/s.
EIS data of the same working electrodes were collected across a
frequency range of 0.1 Hz to 100 KHz while applying a 10 mV sine
wave with the direct current potential set to 0.175 mV (standard
potential of 5 mM K3[Fe(CN)6] in 1 M KCl). CV curves (for bare and
different surface formations) were plotted using chi660d software
for qualitative detection of CRP. EIS data was plotted in the
complex plane diagrams (Nyquist plots) and fitted through ideal
Randle's equivalent circuit. CRP presence at anti-CRP-modified
VACNF electrodes was detected by investigating the changes in
reduction current in CV plots and charge transfer resistance (Rct) in
EIS plots. The decrease in the electrode effective area with the
subsequent surface modifications (i.e. coverage of effective area
with anti-CRP and CRP) results in substantial increase in “Rct”. The
increase of “Rct” after CRP binding on anti-CRP immobilized
electrode surface (decrease in effective surface area) indicates
the detection of CRP. The “Rct” over the specified range of CRP
concentrations was recorded and analyzed for quantification and
determination of LOD. The average values of “Rct”, recorded from
3–5 electrodes immobilized with specific concentration of anti-
CRP for different CRP concentrations (from 50 ng/ml to 5 μg/ml)
were plotted using excel software. The error bars represent the
standard deviation of collected data. The electrochemical curves
(CV and EIS) for bare and subsequent surface modifications with
anti-CRP and CRP were plotted using chi660. The LOD was
calculated from the response equivalent to three times the noise
signal or zero target response (anti-CRP).
2.8. Detection of non-specific control protein
To verify the specificity of CRP immunoassay, CV and EIS data
were collected with identical conditions and parameters as
described earlier for the evaluation of non-specific control proteins
binding on the device. Two such assays were investigated, one
with myoglobin as antigen for anti-CRP antibody immobilized
device and second with CRP as antigen for anti-myoglobin anti-
body immobilized device. The incubation and sensing methods
were the same as employed for specific antigen–antibody immo-
bilization, as described earlier but with high concentrations used
for both types of antigen proteins CRP (2 mg/ml) and myoglobin
(2 mg/ml).
3. Results and discussion
3.1. Electrochemical evaluation of the VACNF NEA sensor
Prior to the surface modifications (immobilizing probes and
targets) of the VACNF NEA, electrochemical characterization of
unmodified or bare electrodes was done utilizing 5 mM K3[Fe
(CN)6] in 1 M KCl to evaluate electrode quality. SEM images of the
individual electrodes were first inspected for exposed fibers tips in
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order to facilitate the electrochemical evaluation and surface
functionalization for probe–target proteins bindings; Fig. S1(c) is
a SEM image of one of the working electrodes in the 33 array
device. The VACNFs tips are the bright dots embedded in SiO2
layer (shaded). AFM micrograph (Fig. S1(d)) of the same electrode
confirms the fiber diameter to be 80 nmwhen estimated at half-
width points on the height profile line section. The combination of
reactive ion etching (RIE) and CMP employed for surface planar-
ization results in protruded VACNF tips around 30–50 nm above
the oxide surface. These projections of VACNF tips above the
surface are primarily due to the resilient nature of the fibers
(Li et al., 2005). The iron ions (Fe[(CN)6]3 /4) present in the
electrolyte solution probe the working electrode surface while
exchanging the electrons with exposed VACNF tips. The exchange
of electrons between the redox ions (Fe[(CN)6]3 /4) and VACNFs
causes the redox reaction given below
Fe½ðCNÞ63 þe2Fe½ðCNÞ64 ð1Þ
The resulting redox current is proportional to the electrode
surface area. Therefore, electrode surface modifications with anti-
CRP probes and CRP targets would block the redox current, thus
providing the means of detection of CRP antigens on anti-CRP
immobilized electrode surface as mentioned earlier. Following the
pre-conditioning of VACNF NEA device as outlined earlier, CV and
EIS measurements for bare and modified electrodes were carried
out. Fig. 1(a) shows the typical steady state sigmoidal behavior of
an individual electrode whereas Fig. S3(a) under Supplementary
Information provides CV curves for three different electrodes
(E1–E3) showing the steady state peaks at a potential difference
of 400 mV (Cassell et al., 2009; Koehne et al., 2009; Arumugam
et al., 2009, 2010; Siddiqui et al., 2010). The steady state behavior
is expected from a spatially patterned isolated nanofiber electrode
because of the absence of overlapping diffusion layers and
predominant radial diffusion of solution ions (Fe[(CN)6]3 /4)
towards the nanoelectrodes.
The CV curves in Fig. 1(a) and Fig. S3(a) show slower electrode
kinetics (ΔΕp400 mV), which, however, can be improved by
electrochemical activation of VACNFs on individual electrodes.
Electrochemical etching in 1.0 M NaOH at 1.2 V for 30 s followed
by soaking in 1 M HNO3 for 15 min would improve the electrode
kinetics (ΔΕp100 mV) and reduction currents while opening the
edge planes of the fibers as reported by Lim et al. (2004). We
observed (data not shown) that even few seconds of electroche-
mical etching of VACNFs results in substantial etching of the fiber
tips causing them to recess into the oxide surface, thereby leaving
holes (shallow VACNFs) on the electrode surface (Siddiqui et al.,
2010; Arumugam et al., 2010). This geometry is not ideal for
antibody immobilization and electrochemical etching therefore
was avoided; however 30 min HNO3 acid soaking was done in
order to improve the signal strength. The effective VACNF density
(number of active fibers) on an individual electrode can be
calculated from the steady-state CV current using the relation,
Iss¼4NnFDCr (Lim et al., 2004; Bard and Faulkner, 2001), where ‘N’
is the number of exposed fibers on the electrode (micro pad), ‘n’ is
the number of electrons exchanged per molecule, ‘F’ is the Faraday
constant, ‘D’ (cm2/s) is the diffusion coefficient of redox species, ‘C’
(mole/cm3) is the bulk concentration of redox species and ‘r’ is
the average radius of VACNFs. Therefore, for Iss¼180 nA,
D¼6.3103 cm2/s, C¼5 mM, and r¼40 nm, the effective number
of VACNFs on the electrode is 1850, which is consistent with
results reported earlier (Arumugam et al., 2009, 2010; Siddiqui et
al., 2010). A higher value of ‘Iss’ implies higher number of VACNFs
active on the patterned electrode and in addition to this, a small
background current (due to non-overlapping radial diffusion)
provides higher detection sensitivity and signal to noise (S/N)
ratio of the electrode. We, however, observed variations in the
effective VACNF density from electrode-to-electrode as well as
device-to-device, which can be easily calculated from the known
values of steady state currents as discussed above. Variations in
the effective VACNF density can be attributed to CNFs of unequal
lengths and/or failure of some catalyst particles to initiate fiber
growth. The effective density of VACNFs and their activation would
eventually result in variations in probe–target protein bindings
and hence, device sensitivity and limit of detection.
Fig. 1(b) shows the impedance spectrum (EIS) for the same
unmodified or bare electrode whereas Fig. S3(b) in the Supple-
mentary Information shows the EIS of three electrodes (E1–E3).
The EIS technique provides better sensitivity than CV by measur-
ing the charge transfer resistance of exposed VANCFs interfaced
with the solution (Hennessey et al., 2009). The complex plane
(Nyquits plots) representation of impedance values in Fig. 1(b) is
recorded which describes a time constant component represent-
ing charge transfer resistance (semicircle) over the frequency
range of 0.1 Hz to 100 KHz and a very small characteristic linear
response representing the mass transport process (Warburg
impedance). The intersection of the semicircle on the horizontal
axis (real impedance) gives the charge transfer resistance (Rct)
value of the specific electrode. We observe a very small or no
Warburg impedance (W) in some cases, which is expected because
of the absence of overlapping diffusion layers in spatially pat-
terned VACNF NEA (Siddiqui et al., 2010). A small but apparent
contribution of ‘W’ in impedance spectrum at lower frequency can
be attributed to mass transport caused by the accumulation of
redox reaction products (oxidized and reduced species) around the
fiber tips. For quantitative values of Rct, the EIS spectrum of the
individual electrode can be modeled using an ideal Randle's
Fig. 1. Electrochemical characterization of VACNF electrode recorded in electrolyte
solution containing 5 mM Fe[CN6]3 /4 in 1 M KCl. (a) CV and (b) EIS; dotted curve
represents the measured data and solid line shows the simulated data using ideal
Randle's circuit (inset).
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equivalent circuit (REC, inset in Fig. 1(b)) comprising of solution
resistance component ‘Rs (Ω)’ in series with time constant
element comprising of charge transfer resistance component ‘Rct
(Ω)’ and double layer capacitance CDL(F) component of REC. A
better agreement between experimental and simulated curves can
be obtained by using frequency-dependent constant-phase-
elements (CPE) replacing pure ‘CDL’ with ‘CPEDL’ and in addition
‘CPEw’ in series with ‘Rct’ as suggested by Hennessey et al. (2009).
However, the ‘Rct’ can easily be quantified from the predictable
intersection of semicircle (experimental curve) on the horizontal
axis (real impedance) in the EIS plot. For three different electrodes
(E1–E3), the CV curves (Fig. S3(a)) and impedance curves (Fig. S3
(b)) apparently follow Ohm's law qualitatively, as the ‘Rct’ values
increase (Rct(E3)4Rct(E2)4Rct(E1)) with a decrease in the slope and
‘Iss’ of the reduction current (negative potential scan) (Iss(E1)
4 Iss(E2)4 Iss(E3)). The higher sensitivity of the EIS technique can
be seen compared to CV in terms of sharp changes in ‘Rct’, than the
respective changes in slope or ‘Iss’.
Binding of specific amount of CRP with surface immobilized
anti-CRP on the VACNFs would block the diffusion of Fe [(CN)6]3 /4
towards the electrode surface. It is, therefore, anticipated that the
subsequent modifications of VACNFs with anti-CRP antibody and
specific concentrations of CRP antigen would block the charge
transfer process between Fe [(CN)6]3 /4 and VACNFs resulting in
the respective decrease of steady state redox current ‘Iss’ or increase
in the ‘Rct’, thus enabling detection of the specific CRP concentration.
3.2. Electrochemical detection of C-reactive protein
CRP detection using fluorescence techniques and labeled func-
tional magnetic nanoparticles based immunoassay has been
developed with high sensitivity, selectivity and lower LOD (Tsai
et al., 2007; Wolf et al., 2004). These immunoassays, however,
involve either CRP protein labeling or additional complex sensing
surface modifications for selective capture of CRP under magnetic
fields, in addition to increasing the cost and time of assay. In
contrast, we employ a label-free and facile detection strategy,
where the binding of specific CRP target protein with surface
immobilized anti-CRP capture protein is investigated by redox
molecule (Fe[(CN)6]3 /4) using well established electrochemical
approaches. A wide range of CRP concentrations, from 50 ng/ml to
5 μg/ml (equivalent to 420 pM to 42 nM) was investigated in order
to evaluate the sensitivity and detection limit of the sensors. The
electrochemical responses of anti-CRP modified electrodes was
considered as the baseline or zero target response and the
corresponding variations in ‘Iss’ and ‘Rct’ with respect to the surface
concentration of CRP was recorded using CV and EIS for CRP
quantification.
Fig. 2(a) shows CV curves recorded for the bare electrode,
Linker\anti-CRP probes and Linker\anti-CRP\CRP target proteins.
The bare electrode response shows a sigmoidal response with
steady state peaks and potential separation (ΔE) of 400 mV. This
peak potential, however, can be reduced to 100 mV by electro-
chemical etching, which has been avoided here to avoid the
possibility of non-specific adsorption in the recessed VACNFs sites
as discussed earlier. Cathodic steady state occurs in the negative
potential range of the CV scan, where the reduction of iron
molecules at the surface of the working electrode takes place
converting the reactants (Fe[(CN)6]3) to products (Fe[(CN)6]4)
while accepting an electron per iron molecule from electrode. In
contrast, anodic steady state occurs in the positive potential range
of the CV scan due to back conversion of Fe[(CN)6]4 to Fe
[(CN)6]3 while donating an electron per iron molecule to the
working electrode. In this process, the reverse current encounters
the double layer capacitance (due to Fe[(CN)6]4 accumulation
near the electrode), resulting in a slower current response. The
forward and reverse CV scans thus give a qualitative measurement
of the surface capacitance, which is proportional to the width of
the double layer. In the case of patterned VACNF NEAs, each fiber
tip is 1 μm apart from its neighbor which minimizes over-
lapping of the double layers from neighboring electrodes, thus
yielding a sigmoidal CV wave in comparison to reversible CV with
well defined redox peeks seen in the case of macro-electrodes
(high density randomly grown VACNFs) in which diffusion layer
overlapping is most prevalent (Periyakaruppan et al., 2013).
The presence of anti-CRP on the VACNF tips (Fig. S2(b)) would
physically insulate the electrode's active surface area. This insulat-
ing layer would reduce the amount of charged species (Fe
[(CN)6]3/4) diffusing towards the electrode which, in turn,
would reduce the amount of electrons exchanged with the VACNFs
and thus, a decrease in the redox currents i.e. flattening of the CV
curve has been recorded for electrodes immobilized with anti-CRP.
The CV response of Linker\anti-CRP (curve (ii)) in Fig. 2
(a) demonstrates a substantial decrease in current compared to
that of bare electrode, which clearly indicates the presence of anti-
CRP. The percentage decrease in the anti-CRP current with respect
to that of the bare electrode can be estimated by calculating the
ratio of two cathodic (reduction) currents on in Fig. 2(a) at
constant potential by using Eq. (2)given below:
ΔIð%Þ ¼ 1 IantiCRP
Ibare
 
E ¼ const

 100 ð2Þ
where ‘ΔI’ represents the change in current, ‘Ianti-CRP’ and ‘Ibare’
represent the reduction currents for anti-CRP immobilized and
Fig. 2. Selected CV curves for bare and subsequent modified electrodes recorded
in electrolyte solution containing 5 mM Fe[CN6]3/4 in 1 M KCl; (a) CV; bare
(i), Linker\anti-CRP (ii), Linker\anti-CRP\CRP and (b) bare (i), Linker\anti-CRP
(ii), Linker\anti-CRP\CRP [0.05–5 μg/ml](iii–viii).
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bare electrode respectively. This percentage decrease in anti-CRP
current gives a measure of the apparent surface coverage of the
electrode by anti-CRP. A 25% decrease in anti-CRP current was
estimated at 300 mV potential. A further decrease in redox current
is seen when CRP binds with anti-CRP immobilized on the
electrode due to further insulation of the active surface area of
the working electrode. A measure of the decrease in CRP reduction
current (‘ICRP’) with respect to ‘Ianti-CRP’ at 300 mV can indicate
the detection of the specific concentration of CRP bound on anti-
CRP immobilized sensor surface. Fig. 2(b) shows CV curves for
bare, Linker\anti-CRP and different CRP concentrations studied
here. The respective decrease in ‘ICRP’ at 300 mV with varying
concentrations is due to the relative coverage of the electrode
surface with CRP. The currents decrease at faster rates for lower
CRP concentrations (0.05–0.5 mg/ml) and at slower rate for higher
concentrations (2.5–5 mg/ml), which is consistent with previous
studies (Li et al., 2005). In addition to the decrease in current
values, a decrease in the surface capacitance with increase in CRP
concentration is also seen from the closeness of the forward and
reverse CV scans. This decrease in surface capacitance results from
the smaller accumulation of Fe[(CN)6]4 molecules near the
VACNF tips, as discussed earlier.
EIS was also used to investigate the interaction of anti-CRP and
CRP with the electrode surface through the ‘Rct’ of the working
electrode to monitor the electron transfer kinetics. Fig. 3(a) shows
the EIS curves recorded for the bare, Linker\anti-CRP and Linker
\anti-CRP\CRP target protein layers on the electrode. Predictably,
the ‘Rct’ values increase from 7 MΩ for the bare electrode to
10 MΩ for Linker\anti-CRP and further with the binding of
specific concentrations of CRP with anti-CRP. The percentage
change in ‘Rct’ for anti-CRP from bare electrode resistance is
calculated as:
ΔRct ¼
RctantiCRP
Rctbare
 
1 ð3Þ
where ‘RctantiCRP ’ denotes the resistance for anti-CRP immobilized
and ‘Rctbare ’ is the resistance for bare electrode. A 30% increase in
‘Rct’ for electrode immobilized with anti-CRP is estimated, which is
close to the 25% change in current from the corresponding CV
analysis discussed earlier. This considerable increase in ‘Rct’, with
the subsequent coverage of the electrode surface (with anti-CRP
and further with specific concentration of CRP), is consistent with
the blockage of redox species reaching to the electrode for charge
exchange. Also, the currents measured in CV and the resistances
measured in EIS are inversely proportional to each other, qualita-
tively obeying the Ohm's law. A distinctly measurable increase in
‘Rct’ values after the surface modifications also indicates the high
sensitivity of EIS compared to the CV technique, as reported by
Hennessey et al. (2009). Fig. 3(b) presents EIS curves for bare,
Linker\anti-CRP and different CRP concentrations studied here. An
increase in ‘Rct’ is seen, as expected, with CRP concentration. Fig. 4
(a) plots the average values of ‘Rct’ for different CRP concentrations
(from 0 to 42 nM); normalization of EIS data as shown in Eq. (4) is
necessary here to incorporate the variations in initial charge
transfer resistance (pad-to-pad and device-to-device variation)
due to the factors discussed in Section 3.1.
ΔRct ¼
Rct
Rct0
1 ð4Þ
where ‘Rct0’ depicts the charge transfer resistance for anti-CRP
modified (Linker\anti-CRP) electrode. In Fig. 4(b) depicting the
Fig. 3. Selected EIS curves for bare and subsequent modified electrodes recorded in
electrolyte solution containing 5 mM Fe[CN6]3 /4 in 1 M KCl; (a) bare (i), Linker
\anti-CRP (ii), linker\anti-CRP\CRP and (b) bare (i), Linker\anti-CRP (ii), Linker\anti-
CRP\CRP [0.05–5 μg/ml](iii–viii).
Fig. 4. Recorded ‘Rct’ values and respective change in charge transfer resistance
‘ΔRct’; (a) ‘Rct’ vs. different concentrations of CRP on anti-CRP immobilized device,
(b) change in ‘Rct0’ (charge transfer resistance for anti-CRP) with respect to different
CRP concentrations.
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normalized values (ΔRct) for each CRP concentration, two slopes
are seen with respect to CRP concentrations. The smaller slope is
observed in the region of lower CRP concentrations (0.42 and
1.06 nM) where the respective % increase in ‘Rct’ is small (13%
per decade of change in CRP concentration). As the CRP concen-
tration rises above 1.06 mM (0.125 μg/ml), ‘Rct’ increases sharply
(60% per decade of change in CRP concentration).
The detection of CRP here shows an LOD (limit of detection) of
90 pM (equivalent to 11 ng/ml), which is calculated by extra-
polating the assay's linear range in the lower concentration region
and looking for a response equivalent to three times the standard
deviation of zero target response (data not shown). The estimated
low detection limit, slightly better than the recently reported
176 pM limit (Bryan et al., 2013), provides sufficient sensitivity for
clinical practice or for point of care testing. The patterned VACNF
NEA is ultrasensitive with small LOD and high S/N ratio because of
its small double layer capacitance around the VACNF tips, absence
of overlapping of diffusion layers from individual neighboring
fibers, and radial instead of linear flow of charged species from
the electrolyte solution towards the nano-sized electrodes. Higher
sensitivity and lower LOD are possible through smaller Rct0; which
indeed requires smaller initial electrode resistance ðRctbare Þ: The
lower ðRctbare Þ can be achieved by VACNF activation (i.e. faster
electrode kinetics) while keeping the electrode surface area
(VACNFs density) constant. Achieving this while preventing
recessed CNFs mentioned earlier requires optimization of the
current approach or seeking new routes, which is currently
under way.
3.3. Specificity test: control protein detection
To confirm the specificity of developed CRP assay, the sensor
was evaluated with non-specific myoglobin antigen. Fig. 5
(a) shows CV curves for bare, Linker\anti-CRP layer and Linker\
anti-CRP\myoglobin layer electrode. It is evident that there is no
non-specific (myoglobin) binding with anti-CRP. However, an
increase in the electrode current (curve (iii)) indicates the possi-
bility of further electrode cleaning and removal of loosely or
unstable bonded anti-CRP off the electrode surface due to the
excessive rinsing after the myoglobin protein incubation. Absence
of non-specific target binding with anti-CRP antibody has been
further confirmed by EIS data in Fig. 5(b). A decrease in the ‘Rct’
after myoglobin incubation on anti-CRP layer is consistent with CV
data. Fig. 5(c), insets in Fig. 5(b), show the average values of ‘Rct’ for
bare and subsequently modified electrodes with probe antibodies
(anti-CRP) and non-specific target antigens (myoglobin). On aver-
age, a 12% reduction in ‘Rct’ after non-specific target protein
binding has been estimated. A similar set of CV and EIS experi-
ments was carried out after incubating CRP as target protein on
anti-myoglobin immobilized electrode. A similar result with a
13% (data not shown) reduction in ‘Rct’ after CRP incubation on
anti-myoglobin immobilized electrodes was observed.
4. Conclusion
A highly selective, facile, low cost and label-free electrochemi-
cal sensing using a nanoelectrode array with patterned vertically
aligned carbon nanofibers has been developed for the detection of
CRP, a biomarker for early stage acute myocardial infraction. The
impedance spectroscopy results show that the approach is capable
of detecting CRP down to 90 pM or 11 ng/ml, a clinically
relevant range, with sufficient sensitivity. The non-specific protein
(myoglobin) binding data confirm the high selectivity of the
developed assay. Integration of the nanoelectrode array with
micro-fluidics capability can provide a portable and multiple
protein detection platform, as desired in diagnosis and for point-
of-care systems. Reducing the initial resistance of the electrodes
can further reduce the LOD, which is currently being investigated.
It is critical to evaluate the sensitivity, detection limit and
selectivity using real biological samples such as blood or plasma
from patients, which is the subject of future work. Since 1–3 μg/ml
concentration of CRP constitutes various risk levels in patients,
there is at least two orders of magnitude to work with for real
samples from the current detection limit of 11 ng/ml.
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